27 matches for your search in the start-up spotlight
rss
05-May-2025
A record number of over 320 innovators from the international life-science community gathered in Munich for the 17th BioVaria, Europe’s premier event for showcasing commercially attractive inventions and start-ups. A highlight was the BioVaria Startup Pitch & Partner Program, where 10 handpicked ...
Innovate Nordics targets Nordic growth companies aiming to establish a presence in the U.S. market
30-Apr-2025
Neogap Therapeutics, a Swedish biotechnology start-up developing personalised immunotherapy for cancer treatment, announced that it has been selected for the Innovate Nordics 2025 Acceleration Program, organised by the Swedish-American Chamber of Commerce in New York (SACCNY) in partnership with ...
Neogap Therapeutics' PIOR technology identifies targets for personalised liver cancer immunotherapies
17-Feb-2025
A new study published in the scientific journal Gut examines how immune system T cells respond to tumours in patients with advanced liver cancer (HCC). Using Neogap Therapeutics' PIOR® software platform, the researchers have identified tumour-specific mutations, which may contribute to the ...
With nearly 1,500 entities, Europe hosts a larger number of cancer-related startups than the US
04-Feb-2025
Cancer remains a major health threat in Europe, which accounts for nearly 25% of global cases and over 20% of deaths, despite having less than 10% of the world's population[1]. Technological advancements are improving survival rates, with European healthcare systems showcasing excellence in ...
“ImmunOs Therapeutics has a very innovative approach to target myeloid checkpoints which are potentially the next major breakthrough in immuno-oncology”
24-Sep-2024
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, announced the closing of a Series C financing round of $11 million. The ...
Insilico Medicine and Inimmune achieved collaboration to revolutionize immunotherapy with AI-driven drug discovery
12-Sep-2024
Insilico Medicine announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico's proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation ...
Swiss start-up NXI Therapeutics extends pre-seed financing to CHF 3.5 million in run-up to larger seed financing
25-Jun-2024
NXI Therapeutics AG, developer of tomorrow’s disruptive immunotherapies by coronin 1 modulation, announces the extension of a pre-Seed financing totalling to 3.5 million CHF. This financing extension comes in the run-up to a larger Seed financing that the company is currently raising. Kickfund ...
"To finance further development, we have founded the biotech start-up Tcelltech"
19-Mar-2024
Making a personalised T cell therapy for cancer patients currently takes at least six months; scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can ...
The development of highly specific T-cell engagers directed against pHLA tumor targets will be quick and easy
26-Oct-2023
The greatest challenge in oncology today is to destroy cancer cells as precisely and accurately as possible without affecting healthy tissue. The focus is on short protein sequences (peptides) presented on the surface of tumor cells by an HLA protein. These pHLA complexes represent attractive ...
Fighting cancer with specially equipped T cells
04-Oct-2023
After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently ...
